Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Legislation
    • Boards and Committees
    • Quality Management System
    • Contact Us
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Report a Problem
Home > News & Updates > Regulatory Updates > Clinical Trials > SRO 685(I)/2023 dated 09-06-2023: Amendments in the Bio Study Rules, 2017

SRO 685(I)/2023 dated 09-06-2023: Amendments in the Bio Study Rules, 2017

Asad Ullah Clinical Trials, SROs June 14, 2023June 16, 2023

The Drug Regulatory Authority of Pakistan, with the Federal Government’s approval, has made amendments to the Bio-Study Rule 2017. Through this amendments, the Application Form (Form-IIA) for BA/BE Studies has been revised to rationalize the requirement for submission of the reference product’s Certificate of Pharmaceutical Products (CoPP). The Notification issued in this regard is as under:-

S.R.O.-685-Form-IIADownload

Share this:

  • Twitter
  • Facebook
  • ← SRO 678(I)/2023 Amendments in the Drug Pricing Policy-2018.
  • Notification: Application on Form-5F (CTD) for Extension in the Contract Manufacturing Permission of Drugs. →
  • DRAP at a Glance
    • What We Do?
    • Vision & Mission
    • CEO’s Message
    • Executive Management
  • Organization
    • Organizational Structure
    • Divisions
    • Policy Board
    • Members of Authority
    • Information and Transparency
    • Strategic Plan
  • Legislation
    • Acts
    • Rules
    • Regulations
    • SROs
    • Notifications
  • Boards and Committees
    • Central Licensing Board
    • Registration Board
    • Medical Devices Board
    • Enlistment Evaluation Committee
    • Clinical Studies Committee
    • Pharmacovigilance RAE Committee
    • Committee on Advertisements
  • Quality Management System
    • Quality Policy
    • Management Reviews
  • Contact Us
  • Drugs
  • Medical Devices
  • Alternative Medicines
  • Controlled Substances
  • Licensing and Inspections
  • Clinical Trials
  • Pharmacovigilance
  • Advertisements
  • General

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:00AM to 04:00PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem